These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

752 related items for PubMed ID: 22811413

  • 1. The PCSK9 decade.
    Lambert G, Sjouke B, Choque B, Kastelein JJ, Hovingh GK.
    J Lipid Res; 2012 Dec; 53(12):2515-24. PubMed ID: 22811413
    [Abstract] [Full Text] [Related]

  • 2. New LDL-cholesterol lowering therapies: pharmacology, clinical trials, and relevance to acute coronary syndromes.
    Sahebkar A, Watts GF.
    Clin Ther; 2013 Aug; 35(8):1082-98. PubMed ID: 23932550
    [Abstract] [Full Text] [Related]

  • 3. Targeting the proprotein convertase subtilisin/kexin type 9 for the treatment of dyslipidemia and atherosclerosis.
    Urban D, Pöss J, Böhm M, Laufs U.
    J Am Coll Cardiol; 2013 Oct 15; 62(16):1401-8. PubMed ID: 23973703
    [Abstract] [Full Text] [Related]

  • 4. Proprotein convertase subtilisin/kexin type 9 (PCSK9) and LDL lowering in the contemporary management of dyslipidemia.
    Switzer MP, Nwosu AC, Juan ZS, Mukherjee D.
    Cardiovasc Hematol Agents Med Chem; 2013 Dec 15; 11(4):281-8. PubMed ID: 24164109
    [Abstract] [Full Text] [Related]

  • 5. Proprotein convertase subtilisin kexin9 (PCSK9): a novel target for cholesterol regulation.
    Basak A, Palmer-Smith H, Mishra P.
    Protein Pept Lett; 2012 Jun 01; 19(6):575-85. PubMed ID: 22519528
    [Abstract] [Full Text] [Related]

  • 6. The promises of PCSK9 inhibition.
    Petrides F, Shearston K, Chatelais M, Guilbaud F, Meilhac O, Lambert G.
    Curr Opin Lipidol; 2013 Aug 01; 24(4):307-12. PubMed ID: 23817198
    [Abstract] [Full Text] [Related]

  • 7. Further LDL cholesterol lowering through targeting PCSK9 for coronary artery disease.
    Cao G, Qian YW, Kowala MC, Konrad RJ.
    Endocr Metab Immune Disord Drug Targets; 2008 Dec 01; 8(4):238-43. PubMed ID: 19075777
    [Abstract] [Full Text] [Related]

  • 8. Proprotein convertase subtilisin/kexin type 9: a new target molecule for gene therapy.
    Banaszewska A, Piechota M, Plewa R.
    Cell Mol Biol Lett; 2012 Jun 01; 17(2):228-39. PubMed ID: 22311433
    [Abstract] [Full Text] [Related]

  • 9. PCSK9 and its modulation.
    Cui CJ, Li S, Li JJ.
    Clin Chim Acta; 2015 Feb 02; 440():79-86. PubMed ID: 25444750
    [Abstract] [Full Text] [Related]

  • 10. PCSK9: From discovery to therapeutic applications.
    Farnier M.
    Arch Cardiovasc Dis; 2014 Jan 02; 107(1):58-66. PubMed ID: 24373748
    [Abstract] [Full Text] [Related]

  • 11. [Inhibition of the protein PCSK9 is a promising target in the prevention of cardiovascular disease].
    Christiansen MK, Jensen HK.
    Ugeskr Laeger; 2015 Mar 09; 177(11):. PubMed ID: 25786699
    [Abstract] [Full Text] [Related]

  • 12. An update on the clinical development of proprotein convertase subtilisin kexin 9 inhibitors, novel therapeutic agents for lowering low-density lipoprotein cholesterol.
    Ling H, Burns TL, Hilleman DE.
    Cardiovasc Ther; 2014 Apr 09; 32(2):82-8. PubMed ID: 24354905
    [Abstract] [Full Text] [Related]

  • 13. PCSK9 inhibition in LDL cholesterol reduction: genetics and therapeutic implications of very low plasma lipoprotein levels.
    Marais AD, Kim JB, Wasserman SM, Lambert G.
    Pharmacol Ther; 2015 Jan 09; 145():58-66. PubMed ID: 25046268
    [Abstract] [Full Text] [Related]

  • 14. [Cholesterol associated to low density lipoproteins (LDL) and vascular risk reduction. Proprotein convertase subtilisin/kexin type 9 (PCSK9): A new therapeutic target].
    Guijarro C, Ruilope LM.
    Med Clin (Barc); 2015 Jul 20; 145(2):67-9. PubMed ID: 26004275
    [No Abstract] [Full Text] [Related]

  • 15. Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibition and the Future of Lipid Lowering Therapy.
    Joseph L, Robinson JG.
    Prog Cardiovasc Dis; 2015 Jul 20; 58(1):19-31. PubMed ID: 25936907
    [Abstract] [Full Text] [Related]

  • 16. The biology of PCSK9 from the endoplasmic reticulum to lysosomes: new and emerging therapeutics to control low-density lipoprotein cholesterol.
    Poirier S, Mayer G.
    Drug Des Devel Ther; 2013 Jul 20; 7():1135-48. PubMed ID: 24115837
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Understanding PCSK9 and anti-PCSK9 therapies.
    McKenney JM.
    J Clin Lipidol; 2015 Jul 20; 9(2):170-86. PubMed ID: 25911073
    [Abstract] [Full Text] [Related]

  • 19. [Proprotein convertase subtilisin/kexin type 9 (PCSK9) and inhibitors].
    Avci A, Demir K, Altunkeser BB.
    Turk Kardiyol Dern Ars; 2014 Oct 20; 42 Suppl 2():56-67. PubMed ID: 25693363
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 38.